Q32 Bio Inc.
QTTB
$6.30
-$0.52-7.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -68.56% | -75.22% | -27.46% | 68.79% | 26.45% |
| Gross Profit | 578.16% | 75.22% | 27.46% | -68.79% | 54.15% |
| SG&A Expenses | 14.12% | -9.98% | -11.05% | 2.04% | 41.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.90% | -59.73% | -48.82% | -23.84% | 30.31% |
| Operating Income | 415.84% | 59.73% | 48.82% | 23.84% | 43.72% |
| Income Before Tax | 507.47% | 58.01% | 44.11% | -1,172.01% | 47.16% |
| Income Tax Expenses | -- | -- | -- | -- | -91.70% |
| Earnings from Continuing Operations | 506.86% | 58.01% | 44.11% | -1,172.01% | 47.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 506.86% | 58.01% | 44.11% | -1,172.01% | 47.58% |
| EBIT | 415.84% | 59.73% | 48.82% | 23.84% | 43.72% |
| EBITDA | 419.10% | 59.95% | 48.98% | 24.01% | 43.91% |
| EPS Basic | 494.47% | 58.57% | 45.18% | -187.47% | 98.47% |
| Normalized Basic EPS | 252.01% | 58.57% | 45.18% | -179.36% | 95.85% |
| EPS Diluted | 493.80% | 58.66% | 45.07% | 85.71% | 98.47% |
| Normalized Diluted EPS | 251.65% | 58.57% | 45.18% | -286.13% | 95.85% |
| Average Basic Shares Outstanding | 3.14% | 1.36% | 1.95% | 1,125.52% | 3,336.99% |
| Average Diluted Shares Outstanding | 3.38% | 1.36% | 1.95% | 422.56% | 3,336.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |